Providers
Map the practical handoffs between referral, screening, treatment, and follow-up.
Road to Access resources
Source-backedDelivery
Referral, Screening, and Triage Pathway
A patient-entry pathway showing how someone can be referred, screened, treated, deferred, redirected, or followed after psychedelic therapy.
- Entry routes
- 5
- Safety principle
- Triage first
- Access risk
- Hidden exclusion
Primary care, psychiatrist, specialist service, trial, patient inquiry
Not every interested patient should move toward dosing
Strict criteria can move access limits upstream into referral
At a glance
What to take from this page
- A credible pathway includes deferral and exit routes, not only a route to treatment.
- Referral design affects equity because geography, specialist access, and prior-treatment rules can filter patients before assessment.
- Triage should connect unsuitable or higher-risk patients back into appropriate care rather than leaving them at a dead end.
Who this helps
Public readers
Understand why interest in psychedelic therapy is not the same as eligibility.
Implementers
Identify where pathway rules can create wait lists, inequity, or unsafe shortcuts.
Entry routes
Primary care
Psychiatrist
Specialist team
Trial route
Patient inquiry
Screening gates
Indication
Approved or funded use
History
Prior treatment and current care
Risk
Medical, psychiatric, and medication review
Feasibility
Support, travel, time, follow-up
The pathway is safe only if deferral and redirection are normal outcomes, not signs that the system failed.
Possible outcomes
Proceed
Defer and stabilize
Redirect to other care
Trial or research route
Follow-up and discharge
Referral and triage decision points
| Decision point | What it asks | Possible route |
|---|---|---|
| Indication fit | Does the person match the approved or funded use? | Proceed, redirect to ordinary care, or consider trial referral |
| Treatment history | Have required prior treatments been tried or ruled out? | Proceed, complete prerequisites, or document exception logic |
| Risk profile | Are medical, psychiatric, medication, or crisis risks manageable? | Proceed with safeguards, defer, or urgent referral |
| Practical feasibility | Can the person attend preparation, administration, and follow-up safely? | Proceed, arrange support, or delay until feasible |
| Post-treatment plan | Who owns follow-up, relapse planning, and outcome capture? | Return to referrer, stay with service, or step up care |
Detailed triage flow
| Gate | What happens | Common outputs |
|---|---|---|
| Route identification | Clarify whether the person is seeking reimbursed medical care, a trial, private off-label treatment, or a non-medical pathway. | Medical referral, trial referral, information only, or redirect away from the medical service. |
| Referral completeness | Check diagnosis, prior treatments, risk history, current medicines, physical health, and urgency. | Book assessment, request records, or return referral with specific missing information. |
| Initial safety screen | Identify crisis risk, psychosis or mania risk, unstable substance use, serious medical contraindications, and practical safety barriers. | Proceed, defer with stabilization plan, urgent escalation, or alternative specialist pathway. |
| Multidisciplinary review | Bring together clinical lead, therapy lead, medicine-governance input where relevant, and site capacity. | Accept into preparation, accept with safeguards, hold for medication review, or decline with handover. |
| Post-treatment routing | Decide whether the person returns to referrer, stays in a specialist pathway, needs relapse monitoring, or needs higher-intensity care. | Discharge summary, registry follow-up, relapse plan, adverse-event review, and re-entry rules. |
The safest triage systems treat redirection as a clinical service output, not as an administrative failure.
Entry routes should be visible
Patients may enter through primary care, a psychiatrist, a specialist mental-health service, an existing provider, a trial, or a direct inquiry. A clinical pathway should say which routes are valid and what information each route must provide.
Without clear entry rules, the system can become informal: people with better networks or more money find a route faster, while higher-risk or underserved patients are screened out without a useful next step.
Screening is a clinical and access gate
Screening usually has to cover indication fit, prior treatment history, psychiatric and medical risks, medication interactions, capacity and consent, acute crisis risk, practical support, and ability to attend follow-up.
These gates are necessary, but they also define real access. If the criteria are narrow, the reimbursed population may be much smaller than public expectation.
Deferral is part of the pathway
A safe pathway should make redirection routine rather than exceptional. Some patients may need stabilization, medication review, crisis support, another evidence-based therapy, or ordinary specialist care before psychedelic therapy is considered.
The pathway should also define what happens after treatment: outcome review, adverse-event capture, relapse planning, return to referrer, or further care if symptoms persist.
A patient should move through named gates
A practical pathway starts before the specialist assessment. The first gate is whether the person is seeking a reimbursed medical intervention, a clinical trial, private off-label care, or a non-medical retreat. Those routes should not be blurred, because each has different legal, clinical, and follow-up obligations.
The second gate is documentation. A service needs enough information to decide whether assessment is appropriate: diagnosis, severity, previous treatments, current medicines, substance-use history, psychosis or bipolar risk, cardiovascular and neurological risks, suicidality, pregnancy status where relevant, and practical support after the session.
The third gate is a decision: proceed to full assessment, request more information, defer until a risk is stabilized, redirect to another pathway, or reject because the person is outside the approved or funded population.
Screening should produce options, not a yes-or-no cliff
A clear pathway has more than one positive outcome. Some people proceed to preparation. Some need medication review before a decision. Some are better served by a different evidence-based treatment. Some need crisis care. Some may be eligible later if risk or practical barriers change.
This matters for equity. If a service only accepts polished referrals, people with fragmented care, limited specialist access, unstable housing, language barriers, or complex comorbidity may never reach assessment even when they could benefit from better triage.
The pathway has to connect back to ordinary care
Psychedelic therapy should not become a one-way door away from normal mental-health services. The referrer, usual treating clinician, or specialist service needs to know the outcome, the safety plan, what symptoms to watch, and who is responsible if the person relapses.
For a reimbursed pathway, that return route is also part of the value case. Payers will want to know whether the intervention reduces later service use, shifts work to another provider, or creates new follow-up obligations that were not costed.